In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Foot: Celera Steps into the Genomic Market

Executive Summary

PE Corp. created Celera to exploit its high-productivity new sequencer, the Prism 3700, and build a broad set of proprietary genomic databases. The move instantly boosted sales of the new sequencer, paying for the expensive start-up in increased revenues to PE's PE Biosystems division and a dramatic increase in market value. Unlike its genomic database competitors, Celera won't charge subscribers royalties and milestones for successful use of the data. To encourage broad and continuing use of the system it hopes will become the industry standard, it plans to make money largely on subscription fees and enlarging its client base, not reach-through rights. But novel genetic data is just the hook for catching clients--Celera hopes to keep them subscribing with a program of continuous annotations and a set of bioinformatics tools that enable a level of in silico experimentation once requiring highly expensive in vitro and in vivo studies. But a raft of new and older competitors stand in the way of its bioinformatics ambitions.

You may also be interested in...



Venter Targets Life Extension With New Genomic Research Company

The former Celera CEO has raised $70 million for a new organization that will use genomic, biochemical and microbiome data to find stem cell-based treatments for aging-related disorders.

Making a New, Big Splash in the Sequencing Market

If one of the first ingredients of a successful tool company deal is to invest as little capital as possible, what then to make of the hefty $27 million raised by Helicos, a developer of high-throughput sequencing systems? The company that successfully integrates the technologies needed for single-molecule sequencing could find a fast and rewarding exit, and neither their investors nor management reject the possibility of a buy-out even before their products hit the market in a few years.

Making a New, Big Splash in the Sequencing Market

If one of the first ingredients of a successful tool company deal is to invest as little capital as possible, what then to make of the hefty $27 million raised by Helicos, a developer of high-throughput sequencing systems? The company that successfully integrates the technologies needed for single-molecule sequencing could find a fast and rewarding exit, and neither their investors nor management reject the possibility of a buy-out even before their products hit the market in a few years.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV001070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel